NASDAQ: OMCL · Healthcare Information Services
Omnicell (OMCL) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Omnicell (OMCL) at $37.58 a share. The stock last closed at $35.44, which puts the model's fair value 6.0% above the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 16 Nov 2026. Omnicell, Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $39.84 to $37.58 (-5.7%). The stock's own trading multiple fell with its price, and the fair value follows it in part: most of the move.
What the model makes of itThe price of $35.44 is 6.0% below it: Fairly valued, on a medium evidence grade.
What's nextNext report on 4 Feb 2027. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give OMCL?
The calibrated range for OMCL over 63 trading days is $30.05 to $44.65. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 13,250 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $31.20 to $44.54. In 63% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally.
Faircurve's model put the fair value of Omnicell at $37.58 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $39.84, so the fair value moved -5.7%. In the model's own words, the stock's own trading multiple fell with its price, and the fair value follows it in part: most of the move. The calibrated range over 63 trading days is $30.05 to $44.65, built from the fair value because there is no live options data for the stock. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is Medium. It covers how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.
Omnicell scores 65 out of 100 on quality against comparable companies, the model's composite of six factors. Balance sheet scores 96, with net debt to EBITDA of -0.76x. Stability scores 88, with EBITDA margin downside volatility of 1.7 pts against a peer median of 11.9 pts. Growth quality scores 46, with trailing revenue growth of 6.5% against a peer median of 10.1%. The model compares Omnicell with Certara, HealthStream, Privia Health Group, Waystar Holding and Doximity.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does OMCL report earnings, and how has the stock reacted?
Omnicell's next earnings report is scheduled for 4 Feb 2027. Companies can move their dates.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across OMCL's last 8 reports, ignoring direction, was 14.0%.
How does OMCL score on business quality?
Omnicell's overall quality score is 65 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 39 | 3.6%ROIC | 2.2% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 90 | 3.24xFCF / net income | |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 46 | 6.5%Revenue growth, trailing | 10.1% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 72 | 0.0%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 96 | -0.76xNet debt / EBITDA | |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 88 | 1.7 ptsEBITDA margin downside volatility, 5y | 11.9 pts |
How does OMCL compare with similar companies?
The companies in healthcare information services closest to Omnicell in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| CERT Certara, Inc. | $11.39 | $11.49 | +0.9% | Fairly valued |
| HSTM HealthStream, Inc. | $27.68 | $27.45 | -0.8% | Fairly valued |
| PRVA Privia Health Group, Inc. | $25.26 | $21.92 | -13.2% | Overvalued |
| WAY Waystar Holding Corp. | $28.11 | $30.05 | +6.9% | Fairly valued |
| DOCS Doximity, Inc. | $32.77 | $32.13 | -2.0% | Fairly valued |
| HQY HealthEquity, Inc. | $104.58 | $104.84 | +0.2% | Low evidence grade |
| BTSG BrightSpring Health Services, Inc. Common Stock | $71.37 | $68.74 | -3.7% | Low evidence grade |
What the comparable companies' multiples alone would give for OMCL, the peer-implied price, is $51.14 a share on this run. The fair value weighs that against the company's own multiple.
All healthcare information services stocks ranked by gap to fair value
Omnicell at a glance
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally.
- Market value
- $1.6B
- Sector
- Healthcare
- Industry
- Healthcare Information Services
- Revenue expected, next twelve months
- $1.2B
- Consensus revenue growth, next fiscal year
- +3.7%
- Analysts with estimates
- 5
- Beta to the US market
- 1.01
- First valued by Faircurve
- 11 Jul 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. OMCL was among them.
How the fair value is worked out: the model prices Omnicell on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for OMCL was $39.84. As of 14 Nov 2026 it is $37.58, a change of -5.7%. The stock's own trading multiple fell with its price, and the fair value follows it in part: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Omnicell's valuation
Is Omnicell stock undervalued or overvalued?
On Faircurve's model, OMCL reads as Fairly valued as of 14 Nov 2026. The model's fair value is $37.58 a share against a last close of $35.44, a gap of +6.0%.
What is OMCL's fair value?
$37.58 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $31.20 to $44.54.
What price range does the model give OMCL?
$30.05 to $44.65 over 63 trading days. Ranges built this way held the price 60% of the time across 13,250 past valuations, refreshed 14 Nov 2026.
When does Omnicell report earnings next?
The next report is scheduled for 4 Feb 2027. Companies can move their dates.
How much has OMCL moved on past earnings reports?
Across its last 8 reports the median two session move was 14.0%, ignoring direction. The largest was +21.2% around the report of 30 Oct 2024.
How confident is the model in this valuation?
The model's evidence grade for OMCL is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on OMCL
The model holds no idea open on OMCL today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on OMCL with their outcomes. A free account is enough.